Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation

Transplant Immunology

Volumn 25, Issue 2-3, 2011, Pages 163-166

  Schlaak, M ^a   Kurschat, P ^a   Shimabukuro Vornhagen, A ^a   Scheid, C ^a   Chemnitz, J ^a   Stadler, R ^b   von Bergwelt Baildon, M ^a   Theurich, S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b KLINIKUM MINDEN   (Germany)

Author keywords

Allogeneic stem cell transplantation; Donor lymphocyte infusion; Graft versus host disease; Graft versus lymphoma effect; Mycosis fungoides; Primary cutaneous t cell lymphoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; CD4 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANOBINOSTAT; PREDNISOLONE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; DRUG WITHDRAWAL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SKIN BIOPSY;

ADULT; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PHOTOPHERESIS; PUVA THERAPY; RECURRENCE; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 80052311225     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.06.008     Document Type: Article

References (14)

1. Corradini P., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172-2176.
2. Duarte R.F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010, 28:4492-4499.
3. Filipovich A.H., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
4. Molina A., et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005, 23:6163-6171.
5. Paczesny S., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
6. Roddie C., Peggs K.S. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011, 11:473-487.
7. Rozmus J., Schultz K.R. Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol 2011, 4:329-342.
8. Schlaak M., et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin 2010, Bone Marrow Transplant.
9. Stadler K., et al. Photopheresis with UV-A light and 8-methoxypsoralen leads to cell death and to release of blebs with anti-inflammatory phenotype in activated and non-activated lymphocytes. Biochem Biophys Res Commun 2009, 386:71-76.
10. Stadler R., Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol 2006, 33:S7-S10.
11. Svennilson J. Novel approaches in GVHD therapy. Bone Marrow Transplant 2005, 35(Suppl 1):S65-S67.
12. Talpur R., et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002, 47:672-684.
13. Trautinger F., et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006, 42:1014-1030.
14. Whittaker S.J., Foss F.M. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007, 33:146-160.